Revvity
Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments.
Latest Revvity Content
Product News
Revvity and Element Biosciences Collaborate To Advance Sequencing-Based IVD Neonatal Testing
Revvity, Inc. announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, co-developed with Element Biosciences, Inc.
Product News
Revvity Announces FDA Clearance for First Automated Free Testosterone Test
Revvity, Inc. (NYSE: RVTY), announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone.
App Note / Case Study
Optimizing Recovery of Microbial DNA for 16S Sequencing
This application note explores techniques for effective sample preparation, including selecting the optimal bead media and how to achieve full sample lysis and DNA recovery in both liquid and solid samples.
App Note / Case Study
Boost the Efficiency of Metagenomic Microbiome Analysis
This application note explores an automated workflow that enhances DNA extraction and sequencing efficiency for stool samples, minimizing human error and delivering high-quality data on microbial communities.
Whitepaper
Improving Long-Read Next Generation Sequencing: What You Should Know
This whitepaper explores the applications of long-read sequencing technologies and best practice strategies to overcome challenges in sample preparation.
App Note / Case Study
Leverage AI To Perform Cell Segmentation on Brightfield Images
This application note showcases how an AI-based module has been trained to analyze brightfield images for cell segmentation, allowing insights into cell proliferation and cell morphology without the need for manual drawing on images.
Product News
Revvity Broadens Relationship With Genomics England To Advance Genomics in the UK
Revvity, Inc. (NYSE: RVTY), announced an expansion of its work with Genomics England that leverages both organizations' expertise and resources to advance critical genomic initiatives across the United Kingdom.
Product News
Revvity Introduces Transcribe AI: Revolutionizing Data Entry in Clinical Laboratories
Revvity, Inc. (NYSE: RVTY) announced the launch of Revvity Transcribe AI, an innovative optical character recognition (OCR) service designed to convert handwritten text on test request forms into a digitized format.
Product News
Revvity’s EUROIMMUN Launches Solution for Specific Typing of Alzheimer’s Disease Associated APOE Gene
APOE genotyping allows assessment of a patient’s risk for adverse effects from new anti-amyloid therapy for Alzheimer’s.
Industry Insight
Getting New Drug Modalities to Market: How Can Your Data Strategy Help?
This article explores the revolution in new drug modalities and the challenges around effective data strategies to support AI efforts.
Advertisement
